E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild cognitive dysfunction |
Disfunzione cognitiva lieve |
|
E.1.1.1 | Medical condition in easily understood language |
Mild cognitive dysfunction |
Disfunzione cognitiva lieve |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10037175 |
E.1.2 | Term | Psychiatric disorders |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The study intends to evaluate the slowing and / or stability of hippocampal atrophy, entorhinal cortex, neocortex and ventricular dilation through the use of a cholinergic precursor (choline alfoscerate) in patients with mild cognitive dysfunction with associated vascular damage. |
Lo studio intende valutare il rallentamento e/o la stabilità dell'atrofia dell'ippocampo, della corteccia entorinale, della neocorteccia e della dilatazione ventricolare mediante l'utilizzo di un precursore colinergico (colina alfoscerato) in pazienti con lieve disfunzione cognitiva con associato danno vascolare. |
|
E.2.2 | Secondary objectives of the trial |
The study intends to evaluate whether the effectiveness of the cholinergic precursor Choline Alfoscerate is superior to that of placebo in the stability and / or improvement of cognitive abilities. Functional performances and changes in mood and motivation will also be monitored. Safety and tolerability of the study drug will be. |
Lo studio intende valutare se l'efficacia del precursore colinergico Colina Alfoscerate è superiore a quella del placebo nella stabilità e/o miglioramento delle capacità cognitive. Verranno inoltre monitorate le performance funzionali e i cambiamenti di umore e motivazione. La sicurezza e la tollerabilità del farmaco in studio saranno. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patient able to understand and sign informed consent and informed consent signed by family member/caregiver 2. Age = 65 years 3. Memory disorders presence evaluated by Neuropsychological Testing (see below): • Mini Mental State Evaluation (MMSE, Folstein et al 1975): score= 24 • Clinical Dementia Rating (CDR) = 0,5 4. Sufficient education to enable the patient to read, write and communicate effectively 5. Indipendent patient in daily, family, work and / or social activities 6. Cooperative patient and able to complete all aspects of the study alone or with the help of a family member 7. Patient living with or in contact with a family member / caregiver who cooperates in the efficacy evaluation 8. MRI performed within 6 (six) months prior to enrollment 9. Presence of at least 2 (two) vascular risk factors listed below: ¿ systemic arterial hypertension ¿ diabetes mellitus ¿ obesity ¿ heart disease (e.g. atrial fibrillation) ¿ dyslipidaemia ¿ hyperhomocysteinemia ¿ tobacco addiction ¿ previous cerebrovascular events ¿ family history of cardio-cerebrovascular diseases |
1. Paziente in grado di comprendere e firmare il consenso informato e il consenso informato firmato dal familiare/caregiver 2. Età = 65 anni 3. Presenza di disturbi della memoria valutata dai Test Neuropsicologici (vedi sotto): • Mini Mental State Evaluation (MMSE, Folstein et al 1975): punteggio = 24 • Valutazione della demenza clinica (CDR) = 0,5 4. Un'istruzione sufficiente per consentire al paziente di leggere, scrivere e comunicare in modo efficace 5. Paziente autonomo nelle attività quotidiane, familiari, lavorative e/o sociali 6. Paziente collaborativo e in grado di completare tutti gli aspetti dello studio da solo o con l'aiuto di un familiare 7. Paziente che vive con o è in contatto con un familiare/caregiver che collabora alla valutazione dell'efficacia 8. Risonanza magnetica eseguita entro 6 (sei) mesi prima dell'arruolamento 9. Presenza di almeno 2 (due) fattori di rischio vascolare sotto elencati: ¿ ipertensione arteriosa sistemica ¿ diabete mellito ¿ obesità ¿ malattie cardiache (es. fibrillazione atriale) ¿ dislipidemia ¿ iperomocisteinemia ¿ dipendenza da tabacco ¿ precedenti eventi cerebrovascolari ¿ storia familiare di malattie cardio-cerebrovascolari |
|
E.4 | Principal exclusion criteria |
1. Overt Alzheimer’s disease 2. All decompensated cardiac disorders 3. Chronic renal failure 4. Severe hepatic insufficiency 5. Incorrect dysthyroidism (Level T3 different from 1,1 - 2,6 nmol/L, T4 different from 60 - 150 nmol/L) 6. Serious ongoing developmental systemic pathologies (eg. malignancies) 7. Any advanced, progressive or unstable disease that, in the opinion of the investigator, could interfere with efficacy or safety assessments or that could put the patient at risk by participation in the study 8. Psychiatric disorders or mental retardation (Severe Depression, Psychosis, Dissociative Syndrome) 9. Alcohol / drug / substance abuse or dependence 10. Diagnosis of Major Depression according to (DSM V), except in cases successfully treated with stable dose of antidepressant (non-anticholinergic) for at least 4 weeks prior to recruitment 11. FrofAny contraindication to treatment or intolerance to choline alfoscerate 12. Patient involved in other clinical trials |
1. Malattia di Alzheimer conclamata 2. Tutti i disturbi cardiaci scompensati 3. Insufficienza renale cronica 4. Insufficienza epatica grave 5. Distiroidismo non corretto (Livello T3 diverso da 1,1 - 2,6 nmol/L, T4 diverso da 60 - 150 nmol/L) 6. Patologie sistemiche evolutive gravi in corso (es. tumori maligni) 7. Qualsiasi malattia avanzata, progressiva o instabile che, a parere dello sperimentatore, potrebbe interferire con le valutazioni di efficacia o sicurezza o che potrebbe mettere a rischio il paziente a causa della partecipazione allo studio 8. Disturbi psichiatrici o ritardo mentale (depressione grave, psicosi, sindrome dissociativa) 9. Abuso o dipendenza da alcol/droghe/sostanze 10. Diagnosi di Depressione Maggiore secondo (DSM V), tranne nei casi trattati con successo con dose stabile di antidepressivo (non anticolinergico) per almeno 4 settimane prima del reclutamento 11. Per qualsiasi controindicazione al trattamento o intolleranza alla colina alfoscerato 12. Pazienti coinvolti in altri studi clinici |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The slowing and / or stability of hippocampal atrophy, entorhinal cortex, neocortex and ventricular dilation through the use of a cholinergic precursor (choline alfoscerate) in patients with mild cognitive dysfunction with associated vascular damage will be measured using the MMSE scale at the final visit compared to baseline. |
Il rallentamento e/o la stabilità dell'atrofia dell'ippocampo, della corteccia entorinale, della neocorteccia e della dilatazione ventricolare attraverso l'uso di un precursore colinergico (colina alfoscerato) in pazienti con lieve disfunzione cognitiva con associato danno vascolare sarà misurato utilizzando la scala MMSE alla visita finale rispetto alla baseline. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The final visit compared to baseline. |
Visita finale rispetto alla baseline. |
|
E.5.2 | Secondary end point(s) |
The stability and/or improvement of cognitive abilities will be assessed through the use of neuropsychological scales that will evaluate the cognitive performance of patients (executive, memory, visual-constructive, linguistic and attentional functions) at the end of the study compared to the baseline visit. Functional performances and changes in mood and motivation will be evaluated with specific neuropsychological tests. |
La stabilità e/o il miglioramento delle capacità cognitive sarà valutata attraverso l'utilizzo di scale neuropsicologiche che valuteranno le prestazioni cognitive dei pazienti (funzioni esecutive, mnemoniche, visuo-costruttive, linguistiche e attenzionali) al termine dello studio rispetto alla baseline. Le prestazioni funzionali ei cambiamenti di umore e motivazione saranno valutati con specifici test neuropsicologici. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of the study compared to the baseline. |
Termne dello studio rispetto alla baseline. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |